Cancer genomics research aims to advance personalized oncology by finding and targeting
specific genetic alterations associated with cancers. In genome-driven oncology, treatments …

Cancer biomarkers have transformed current practices in the oncology clinic. Continued
discovery and validation are crucial for improving early diagnosis, risk stratification, and …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Although the field of mass spectrometry-based proteomics is still in its infancy, recent
developments in targeted proteomic techniques have left the field poised to impact the …

Tumor tissue processing methodologies in combination with data‐independent acquisition
mass spectrometry (DIA‐MS) have emerged that can comprehensively analyze the …

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is
applying the latest generation of proteomic technologies to genomically annotated tumors …

The utility of mass spectrometry (MS)-based proteomic analyses and their clinical
applications have been increasingly recognized over the past decade due to their high …

Availability of a suite of biomarkers for early detection, stratification into distinct subtypes,
and monitoring progression or response to therapy promises significant improvements in …

The complexities of tumor genomes are rapidly being uncovered, but how they are regulated
into functional proteomes remains poorly understood. Standard proteomics workflows use …

Cancer impacts each patient and family differently. Our current understanding of the disease
is primarily limited to clinical hallmarks of cancer, but many specific molecular mechanisms …